Breakthroughs that change patients' lives

Pfizer is a proven leader in developing new medicines for genitourinary (GU) cancers with a longstanding commitment to transforming care and outcomes for people with these pervasive and hard-to-treat cancers.

Our commitment extends to include programs and support for GU cancers



We are proud of our portfolio of six approved medicines to treat people living with prostate, kidney and bladder cancers, in the United States



Our clinical investments and collaborations in the science of GU cancers have allowed us to gain deep experience in understanding the science of GU cancers. These ongoing collaborations have allowed us to develop a robust portfolio and late-stage pipeline



We work closely with the entire cancer community to better understand the needs of people living with GU cancers, and their families and caregivers



©2022 Pfizer Inc. All rights reserved.

